Beyond Diabetes: Bayer's KERENDIA Poised to Redefine Chronic Kidney Disease Treatment

WHIPPANY, NJ – June 02, 2026 – The world of nephrology is turning its attention to Glasgow, Scotland, where Bayer is set to unveil pivotal data that could fundamentally alter the treatment landscape for chronic kidney disease (CKD). At the 63rd European Renal Association (ERA) Congress this week, the pharmaceutical giant will present the first full results from its FIND-CKD study, evaluating the drug KERENDIA (finerenone) in patients with CKD without diabetes—a massive and largely underserved population. The announcement signals a potential paradigm shift, moving a successful therapy beyond its initial indication and into a vast new territory of unmet medical need.

For years, the narrative around advanced CKD therapies has been closely tied to type 2 diabetes, a primary driver of kidney failure. KERENDIA itself was first approved for this group. But the upcoming presentation promises to broaden that conversation significantly, offering a glimmer of hope for the more than 400 million people worldwide whose kidney decline is not linked to diabetes.

A New Horizon for a Silent Epidemic

Chronic kidney disease is a progressive and often silent condition affecting an estimated 850 million people globally. It's a slow, insidious decline in the kidneys' ability to filter waste from the blood, which can lead to cardiovascular complications, kidney failure, and the need for life-altering dialysis or transplantation. While diabetes is a well-known cause, it is only part of the story. More than half of all CKD cases are estimated to be non-diabetic, stemming from a range of issues including hypertension, genetic factors, and inflammatory conditions.

It is this silent majority that Bayer's FIND-CKD trial was designed to address. The Phase III study investigated whether KERENDIA, when added to the standard of care, could slow the progression of kidney disease in adults without diabetes. The anticipation surrounding the results is immense. A positive outcome would represent one of the most significant therapeutic advances for this patient group in years.

Adding another layer of importance, Bayer will also present a subgroup analysis from the study focusing on patients with glomerulonephritis. This complex group of diseases, characterized by inflammation of the kidney's tiny filters, is a leading cause of kidney failure and has notoriously few effective treatments. A proven therapy for this specific condition would be a landmark achievement.

“People living with CKD need additional options grounded in evidence that reflects the diversity of their disease,” said Carolina Aldworth, M.D., MSc, Executive Medical Director at Bayer, in a statement preceding the congress. The FIND-CKD data is the company's first major step toward providing that evidence for the non-diabetic population.

Deconstructing the Science: A Broader Cardiorenal Battlefield

To understand the potential of KERENDIA, one must look at its unique mechanism. The drug, finerenone, is a non-steroidal mineralocorticoid receptor antagonist (MRA). It works by blocking the overactivation of the mineralocorticoid receptor in the heart and kidneys, a key pathway that drives inflammation and fibrosis—the scarring that ultimately destroys organ function. While older, steroidal MRAs exist, they often come with a higher risk of side effects like hyperkalemia (dangerously high potassium levels), limiting their use. KERENDIA was engineered to be more selective, offering a potentially better-tolerated way to interrupt this damaging process.

The drug has already proven its worth. Its initial approvals were based on the monumental FIDELIO-DKD and FIGARO-DKD trials, which collectively involved over 13,000 patients with CKD and type 2 diabetes. These studies demonstrated that KERENDIA significantly reduced the risk of both kidney disease progression and cardiovascular events, establishing it as a key pillar of treatment in the diabetic population.

Now, Bayer is aiming to provide an even more comprehensive picture with its INFINITY pooled analysis, also being presented at the ERA congress. This ambitious analysis combines the data from the previous diabetic trials with the new FIND-CKD results from non-diabetic patients. By pooling individual participant data, researchers can gain unprecedented statistical power to evaluate the drug's efficacy and safety across the entire spectrum of CKD, providing a holistic view of its cardiorenal protective effects.

Reshaping the Clinical and Competitive Landscape

The treatment landscape for CKD has been revolutionized in recent years, most notably by the rise of SGLT2 inhibitors. Drugs like AstraZeneca's Farxiga and Eli Lilly's Jardiance, originally developed for diabetes, have shown profound kidney-protective benefits in patients with and without diabetes, becoming a new standard of care. This sets a high bar for any new therapy entering the space.

However, the complexity of CKD means there is rarely a single magic bullet. The disease is driven by multiple biological pathways, and experts believe the future of treatment lies in combination therapy. KERENDIA's distinct mechanism, targeting inflammation and fibrosis via the MR pathway, makes it a potentially ideal partner for SGLT2 inhibitors, which work primarily by reducing pressure within the kidney's filtering units. “We are moving from a one-size-fits-all approach to a more personalized strategy in nephrology,” noted one clinical researcher not involved in the study. “Having another tool with a different mechanism, like finerenone, could be transformative, especially for patients who don't respond to or can't tolerate other therapies.”

If the FIND-CKD data is positive, it could trigger a rapid reshaping of clinical practice guidelines. For the first time, clinicians might have a powerful, evidence-backed MRA specifically approved for the vast non-diabetic CKD population, giving them a new weapon to slow disease progression and prevent cardiovascular events.

Bayer's Strategic Gambit: Building a Cardiorenal Powerhouse

The upcoming data release is far more than an isolated scientific event; it is a cornerstone of Bayer’s long-term corporate strategy. The company has invested heavily in establishing a formidable cardiorenal franchise, built around KERENDIA as its centerpiece. This effort is embodied by the massive FINEOVATE clinical program, an umbrella for 12 Phase III studies, including the MOONRAKER program in heart failure and the THUNDERBALL program dedicated to CKD.

This strategy is already bearing fruit. In July 2025, Bayer secured a crucial FDA approval for KERENDIA to treat patients with a common type of heart failure (HFpEF/HFmrEF), based on the successful FINEARTS-HF study. This expansion into heart failure underscores the deep biological connection between the heart and the kidneys and positions KERENDIA as a therapy that addresses the entire cardiorenal continuum.

The potential expansion into non-diabetic CKD would be a massive commercial victory, opening up a market even larger than the diabetic one and justifying the billions invested in research and development. It would solidify Bayer’s position in a fiercely competitive market, standing alongside giants like AstraZeneca, Eli Lilly, and Novo Nordisk, all of whom are vying for dominance in the multi-billion dollar cardiorenal space. As the lights go up in Glasgow, the data presented will not only determine the future for millions of patients but will also signal the next major move in the high-stakes chess game of modern pharmaceuticals.